CNTA Centessa Pharmaceuticals plc: institutional ownership and insider trading
5 funds reported holding $142M of Centessa Pharmaceuticals plc in their latest 13F filings; in Q2 2026 funds net bought $0, with 0 new positions and 160 funds selling out; over the last 12 months insiders bought $0 and sold $13.3M on the open market; over its last four quarters it reported revenue of $0 and net income of −$251M.
CNTA revenue and earnings
- Quarter ended Mar 31, 2026: revenue $0, net income −$79.2M, EPS -0.52
- Quarter ended Dec 31, 2025: revenue $0, net income −$66.2M, EPS -0.47
- Quarter ended Sep 30, 2025: revenue $0, net income −$54.9M, EPS -0.41
- Quarter ended Jun 30, 2025: revenue $0, net income −$50.3M, EPS -0.38
Largest institutional holders of CNTA
- JANUS HENDERSON GROUP PLC (JHG) — $139M
- Cubist Systematic Strategies, LLC — $2.52M
- WOLVERINE TRADING, LLC — $556K
- Brooklyn Investment Group — $296K
- Point72 Asia (Singapore) Pte. Ltd. — $162K
Recent CNTA insider trades
- Jun 24, 2026: Medicxi Growth I LP sold 19,963,157 shares ($0)
- Jun 24, 2026: Index Ventures Life Vi (Jersey) L.P. sold 9,961,789 shares ($0)
- Mar 26, 2026: Anderson Karen M. sold 41,076 shares ($1.24M)
- Mar 26, 2026: Weinhoff Gregory M sold 23,998 shares ($720K)
5%+ owners
- Avoro Capital Advisors LLC: 7.4% (Schedule 13G/A, filed May 15, 2026)
Who owns the most CNTA stock?
The largest institutional holders of Centessa Pharmaceuticals plc in the latest 13F filings are JANUS HENDERSON GROUP PLC (JHG) ($139M), Cubist Systematic Strategies, LLC ($2.52M), WOLVERINE TRADING, LLC ($556K).
Are insiders buying or selling CNTA?
Over the last 12 months insiders bought $0 and sold $13.3M of Centessa Pharmaceuticals plc stock on the open market (SEC Form 4).
What was CNTA's revenue last quarter?
Centessa Pharmaceuticals plc reported revenue of $0 for the quarter ended March 31, 2026, with net income of −$79.2M.
Which ETFs hold CNTA?
7 ETFs and mutual funds hold it among their top 100 positions, including ARBCX, GAAGX, PGLSX, AEDFX.